Claims for Patent: 6,566,099

Summary for Patent: 6,566,099

Title:	Nucleic acid encoding a chimeric polypeptide
Abstract:	A therapeutic method whereby an individual suspected of having an .alpha.-galactosidase A deficiency, such as Fabry disease, is treated either with (1) human cells that have been genetically modified to overexpress and secrete human .alpha.-gal A, or (2) purified human .alpha.-gal A obtained from cultured, genetically modified human cells.
Inventor(s):	Selden; Richard F. (Wellesley, MA), Borowski; Marianne (Winthrop, MA), Gillispie; Frances P. (Lexington, MA), Kinoshita; Carol M. (Bedford, MA), Treco; Douglas A. (Arlington, MA), Williams; Melanie D. (Natick, MA)
Assignee:	Transkaryotic Therapies, Inc. (Cambridge, MA)
Application Number:	09/491,759
Patent Claims:	1. A DNA molecule comprising a sequence that encodes the signal peptide of hGH linked to glucocerebrosidase. 2. The DNA molecule of claim 1, further comprising the first intron of hGH. 3. A cell comprising the DNA molecule of claim 1. 4. The cell of claim 3, wherein the cell is a human cell. 5. The cell of claim 3, wherein the cell is a fibroblast. 6. The cell of claim 3, wherein the cell is an epithelial cell, an endothelial cell, a lymphocyte, a bone marrow cell, a glial cell, a hepatocyte, a keratinocyte, a muscle cell, a neural cell, a Bowes melanoma cell, a Daudi cell, a HeLa cell, an HL-60 cell, an HT1080 cell, a Jurkat cell, a KB carcinoma cell, a K-562 leukemia cell, an MCF-7 breast cancer cell, a MOLT-4 cell, a Namalwa cell, a Raji cell, an RPMI 8226 cell, a U-937 cell, a WI-38VA13 subline 2R4 cell, a 2780AD ovarian carcinoma cell, a WI-38 cell, or an MRC-5 cell. 7. A polypeptide comprising the signal peptide of hGH linked to glucocerebrosidase. 8. A method of obtaining glucocerebrosidase, the method comprising (a) culturing the cell of claim 3, and (b) isolating glucocerebrosidase from the cell, or the culture medium of the cell.

Details for Patent 6,566,099

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2016-09-13
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2016-09-13
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2016-09-13